A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed

BACKGROUND: Crizotinib is the approved treatment for advanced non-small cell lung cancers (NSCLCs) of anaplastic lymphoma kinase (ALK) fusion. Failure of crizotinib treatment frequently involves drug intolerance or resistance. Comparison of using second-generation ALK inhibitors in this setting rema...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Chih-Hsi Scott, Tung, Pi-Hung, Huang, Allen Chung-Cheng, Wang, Chin-Chou, Chang, John Wen-Cheng, Liu, Chien-Ying, Chung, Fu-Tsai, Fang, Yueh-Fu, Guo, Yi-Ke, Yang, Cheng-Ta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988977/
https://www.ncbi.nlm.nih.gov/pubmed/33761908
http://dx.doi.org/10.1186/s12885-021-08005-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988977/
https://www.ncbi.nlm.nih.gov/pubmed/33761908
http://dx.doi.org/10.1186/s12885-021-08005-1

Ejemplares similares